Viridian Therapeutics, Inc. VRDN
28.49 USD -0.06 (-0.21%)
At closeNov 6, 2026, 4:00 PM EST
28.48 -0.01 -0.04%
After hours · Nov 6, 4:00 PM ET
27.86 Day range 29.46
13.18 52-week range 34.29
- YTD
- -8.45%
- 1 year
- +3.60%
News
benzinga.com Viridian Therapeutics To Present VRDN-008 Phase 1 Data And Outline FcRn Portfolio Development Plans On Monday, November 9, 2026, At 8:00 a.m. ET Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today…- benzinga.com Leerink Partners Maintains Outperform on Viridian Therapeutics, Raises Price Target to $54 Leerink Partners analyst Thomas Smith maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $50 to $54.
benzinga.com RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $41 RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $38 to $41.
benzinga.com Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $42 Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $39 to $42.
benzinga.com Wells Fargo Maintains Overweight on Viridian Therapeutics, Raises Price Target to $34 Wells Fargo analyst Derek Archila maintains Viridian Therapeutics (NASDAQ:VRDN) with a Overweight and raises the price target from $31 to $34.- benzinga.com Evercore ISI Group Maintains Outperform on Viridian Therapeutics, Raises Price Target to $33 Evercore ISI Group analyst Maneka Mirchandaney maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $26 to $33.
- benzinga.com Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $42 Wedbush analyst Laura Chico maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $41 to $42.
benzinga.com McDonald's To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Thursday Analysts raised targets for PTRN, VRDN, JBLU and GTM; cut targets for BROS, CSCO and CAVA. Cisco was downgraded; JetBlue upgraded.
seekingalpha.com Viridian Therapeutics: Strong Start For Lumvoa, VRDN-008 Data Ahead Viridian Therapeutics delivered a strong Q3, with Lumvoa net sales of $24.7 million, far surpassing consensus expectations. Competition is intensifying with Roche's Enspryng entering the TED market,…
benzinga.com HC Wainwright & Co. Maintains Buy on Viridian Therapeutics, Raises Price Target to $40 HC Wainwright & Co. analyst Douglas Tsao maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $22 to $40.
marketbeat.com What Viridian Therapeutics (VRDN) Said on Its Q3 Earnings Call Viridian Therapeutics NASDAQ: VRDN reported $24.7 million in net product revenue from Lumvoa in the thyroid eye disease treatment's first quarter on the market, with more than 100 patients having…- benzinga.com Needham Maintains Buy on Viridian Therapeutics, Raises Price Target to $38 Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $34 to $38.
seekingalpha.com Viridian Therapeutics, Inc. (VRDN) Q3 2026 Earnings Call Transcript Viridian Therapeutics, Inc. (VRDN) Q3 2026 Earnings Call Transcript
zacks.com Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Beats Revenue Estimates Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1.01. This compares to a loss of $0.34 per share a year ago.
benzinga.com Viridian Therapeutics Q3 2026 Earnings Call Transcript Viridian Therapeutics (NASDAQ:VRDN) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…- benzinga.com Viridian Therapeutics Q3 EPS $(0.81) Beats $(1.00) Estimate, Sales $25.752K May Not be Comparable To $5.084M Estimate Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(1.00) by 19 percent. This is a 138.24 percent decrease over losses of…
businesswire.com Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for…
benzinga.com Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy Roche earns FDA approval for Enspryng in thyroid eye disease, offering the only at-home subcutaneous treatment for TED.- benzinga.com RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $38 RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $36 to $38.
benzinga.com Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying Biotechnology investing is a strange corner of the market. A company can own a drug that may eventually produce billions of dollars in sales and still find itself scrambling to raise enough cash to…
benzinga.com RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $36 RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $35 to $36.
benzinga.com Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $39 Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $38 to $39.
benzinga.com Viridian Therapeutics Q2 EPS $(1.05) Misses $(1.02) Estimate, Sales $233.000K Beat $22.308K Estimate Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(1.02) by 2.94 percent. This is a 5 percent decrease over losses of…- benzinga.com RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $35 RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $34 to $35.
benzinga.com Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $38 Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $35 to $38.- benzinga.com Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $43 Wedbush analyst Laura Chico maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $32 to $43.
- benzinga.com Needham Maintains Buy on Viridian Therapeutics, Raises Price Target to $34 Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $32 to $34.
- benzinga.com Wells Fargo Upgrades Viridian Therapeutics to Overweight, Raises Price Target to $31 Wells Fargo analyst Derek Archila upgrades Viridian Therapeutics (NASDAQ:VRDN) from Equal-Weight to Overweight and raises the price target from $20 to $31.
benzinga.com Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease FDA approves Viridian Therapeutics' Lumvoa for thyroid eye disease. Immediate commercial launch scheduled with full patient support.
benzinga.com Stock Market Today: Nasdaq, Dow S&P 500 Futures Jump As Trump Admin Says US, Iran Will 'Stand Down' For Now— Verizon, HP, Universe Pharmaceuticals In Focus (UPDATED) U.S. stock futures rose on Monday, as the Dow Jones, Nasdaq 100, and S&P 500 indices rose, following Friday's mixed close.
benzinga.com Why Universe Pharmaceuticals Shares Are Trading Higher By Around 228%; Here Are 20 Stocks Moving Premarket Universe Pharmaceuticals Inc (NASDAQ: UPC) surged 228.4% to $9.72 in pre-market trading after announcing acquisition of Best Praise International for $10.75 million.- benzinga.com Needham Reiterates Buy on Viridian Therapeutics, Maintains $32 Price Target Needham analyst Serge Belanger reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $32 price target.
benzinga.com Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday U.S. stock futures up, watch Concentrix Corp, Lantheus Holdings, AeroVironment, Viridian Therapeutics, Universe Pharmaceuticals for earnings and news.- benzinga.com Viridian Therapeutics Receives FDA Approval For Lumvoa For The Treatment Of Thyroid Eye Disease; Co. Plans To Launch Lumvoa Immediately First approved treatment for thyroid eye disease (TED) with labeling that includes data for both active and chronic TED -- In two pivotal phase 3 clinical trials, Lumvoa treatment showed rapid,…
- benzinga.com Viridian Therapeutics Strikes Commercial Manufacturing Services Agreement With WuXi Biologics To Produce, Supply Veligrotug Drug Substance, Drug Product https://www.sec.gov/ix?doc=/Archives/edgar/data/1590750/000119312526239246/d111034d8k.htm
- benzinga.com Evercore ISI Group Maintains Outperform on Viridian Therapeutics, Lowers Price Target to $26 Evercore ISI Group analyst Maneka Mirchandaney maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and lowers the price target from $27 to $26.
- benzinga.com RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $34 RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $30 to $34.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Rockwell Automation Posts Upbeat Q2 Results, Joins EverQuote, DigitalOcean And Other Big Stocks Moving Higher On Tuesday Dow Jones up 200 points, Rockwell Automation shares rise 10.8% on strong earnings and raised guidance. Other big gainers include EverQuote, Sterling Infrastructure, and DigitalOcean.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com Viridian Therapeutics Q1 EPS $(0.90) Beats $(1.05) Estimate, Sales $141.000K Beat $27.500K Estimate Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(1.05) by 14.29 percent. This is a 3.45 percent decrease over losses…- benzinga.com Viridian Therapeutics Elegrobart Achieves 50-54% Proptosis And 61% Diplopia Responder Rates In Phase 3 REVEAL-2, Becoming Only Subcutaneous Program With Two Positive TED Pivotal Trials - REVEAL-2 met its primary endpoint with a highly statistically significant treatment effect -- Elegrobart Q4W and Q8W achieved 50% and 54% proptosis responder rates (PRR) at week 24, respectively,…
- benzinga.com Truist Securities Maintains Buy on Viridian Therapeutics, Lowers Price Target to $33 Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price target from $36 to $33.
benzinga.com Amazon To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Wednesday Wall Street analysts changed outlook on top names. See all changes on Benzinga's analyst ratings page. Price targets and ratings altered for CING, WING, DEFT, FANG, PJT, DOCS, and AMZN.- benzinga.com Wedbush Maintains Outperform on Viridian Therapeutics, Lowers Price Target to $31 Wedbush analyst Laura Chico maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and lowers the price target from $37 to $31.
benzinga.com Top 3 Health Care Stocks Which Could Blast Off This Quarter Undervalued companies in health care sector with low RSI values present buying opportunity: PepGen Inc (PEPG), KALA BIO Inc (KALA), Viridian Therapeutics Inc (VRDN)- benzinga.com Goldman Sachs Maintains Buy on Viridian Therapeutics, Lowers Price Target to $31 Goldman Sachs analyst Richard Law maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price target from $36 to $31.
- benzinga.com RBC Capital Maintains Outperform on Viridian Therapeutics, Lowers Price Target to $30 RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and lowers the price target from $42 to $30.
benzinga.com Why Is Viridian Therapeutics Stock Sinking Monday? Viridian shares fall after Amgen TEPEZZA Phase 3 data shows stronger efficacy, raising concerns over elegrobart's position in the TED market.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session